Nanoparticle-based Drug Delivery · Journal article

Review of Nanoparticle-Based Therapeutics: Comparative Clinical Translation, Safety Barriers, and Regulatory Challenges

Nano Life · August 14, 2026

Expert Guidance Why this matters to you Expert discussion

A consensus or society position rather than new primary data.

AI Summary

This is a narrative review of nanoparticle-based therapeutics across disease domains, addressing clinical translation pathways, safety concerns, and regulatory challenges. The abstract does not report original clinical trial data, efficacy metrics, or comparative outcomes, making it unsuitable as evidence for a specific therapeutic claim but appropriate as background or guidance on the field.

What was studied

Narrative review. Nanoparticle-based therapeutic approaches across multiple disease domains; no specific patient population enrolled..

Key findings

Nanoparticles (1–100 nm) enable targeted drug delivery, enhanced efficacy, and reduced systemic toxicity compared to conventional approaches Major nanoparticle types reviewed: lipid-based, polymeric, metallic, magnetic, and carbon-based Applications span cancer, infectious diseases, neurological disorders, and cardiovascular conditions

Safety

Abstract does not report efficacy metrics, safety data, or comparative outcomes for any specific nanoparticle therapy or disease indication Nanoparticles (1–100 nm) enable targeted drug delivery, enhanced efficacy, and reduced systemic toxicity compared to conventional approaches

Who this may help

This review synthesizes current knowledge on nanomedicine translation and regulatory hurdles to inform strategy rather than provide evidence for a specific treatment. Clinicians should consult disease-specific trials and regulatory summaries for efficacy and safety data.

Plain-language summary

A narrative review synthesizing evidence on nanoparticle therapeutics, safety, and regulatory pathways to inform clinical translation strategy rather than report original research findings.

Study design

As stated by the source record.

MethodsNarrative review

Reported figures

Quoted from the source exactly as published.

Nanoparticle size range1 to 100 nm

Clinical bottom line

Caveats

Abstract does not report efficacy metrics, safety data, or comparative outcomes for any specific nanoparticle therapy or disease indication
No quantification of literature coverage or systematic review methodology provided
Regulatory challenges and barriers are described qualitatively but without specific approval timelines, rejection rates, or regulatory precedent
Clinical translation status for individual nanoparticles not detailed in abstract

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Review article; no primary data collection or experimental design described.

Directness

moderate

Addresses clinical translation and regulatory barriers directly, but abstract does not report specific clinical outcomes.

Consistency

insufficient

No comparison of conflicting evidence or synthesis of heterogeneous findings presented in abstract.

Risk of bias

insufficient

Review methodology, inclusion criteria, and bias assessment not described in abstract.

Sample adequacy

insufficient

Number of articles reviewed and coverage of literature not quantified in abstract.

Source abstract

Nanotechnology has emerged as a transformative approach in modern medicine, offering innovative strategies for disease diagnosis, treatment, and prevention. Nanoparticles, typically ranging from 1 to 100 nm in size, possess unique physicochemical properties that enable targeted drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity. This review provides a comprehensive overview of the major types of nanoparticles used in disease treatment, including lipid-based, polymeric, metallic, magnetic, and carbon-based nanoparticles. Their applications across various disease domains, such as cancer, infectious diseases, neurological disorders, and cardiovascular conditions, are discussed. In addition, the benefits and limitations associated with nanoparticle-based therapies, including safety concerns and regulatory challenges, are critically examined. Finally, future perspectives on the clinical translation and advancement of nanomedicine are highlighted.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Nanoparticle-based Drug DeliverySara K. GhodeifAlaa A. El-SaidNahla S. El‐Shenawy